Neuren Pharmaceuticals (ASX:NEU) - Non Executive Chair, Patrick Davies
Non Executive Chair, Patrick Davies
Source: Neuren Pharmaceuticals
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Neuren Pharmaceuticals (NEU) receives a Notice of Allowance from the US Patent and Trademark Office for NNZ-2591 to treat autism
  • The patent is titled “Bicyclic compounds and methods for their use in treating autism” and extends to July 2034
  • Neuren is currently developing NNZ-2591 to treat a range of serious lifelong neurological disorders
  • The aim of NNZ-2591 is to mimic the normal function of the brain and help control and normalise the biological process
  • Shares in Neuren are up 3.48 per cent on the market and are trading at $2.08 at 1:57 pm AEDT

Neuren Pharmaceuticals (NEU) has received a Notice of Allowance from the US Patent and Trademark Office for NNZ-2591 to treat autism.

The patent is titled “Bicyclic compounds and methods for their use in treating autism” and extends to July 2034.

Neuren is currently developing NNZ-2591 to treat Phelan-McDermid, Angelman, Prader-Willi and Pitt Hopkins syndromes, all of which are serious lifelong neurological disorders.

The aim of NNZ-2591 is to mimic the normal function of the brain and help control and normalise the biological process.

CEO Jon Pilcher is excited by the granting of the patent as it could help understand autism in the United States.

“We have seen that the mechanism of action of NNZ-2591 appears to have broad utility in neurodevelopmental disorders,” Mr Pilcher said.

“Given that autism is estimated to affect one in 160 children, the granting of this important US patent could potentially enable a very large future opportunity as more becomes known about the causes of autism.”

Shares in Neuren were up 3.48 per cent on the market and were trading at $2.08 at 1:57 pm AEDT.

NEU by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…